RT Book, Section A1 Katzung, Bertram G. A1 Kruidering-Hall, Marieke A1 Tuan, Rupa Lalchandani A1 Vanderah, Todd W. A1 Trevor, Anthony J. SR Print(0) ID 1180558049 T1 Antimycobacterial Drugs T2 Katzung & Trevor's Pharmacology: Examination & Board Review, 13e YR 2021 FD 2021 PB McGraw-Hill Education PP New York, NY SN 9781260117127 LK accessmedicine.mhmedical.com/content.aspx?aid=1180558049 RD 2024/03/28 AB The chemotherapy of infections caused by Mycobacterium tuberculosis, M leprae, and M avium-intracellulare is complicated by numerous factors, including (1) limited information about the mechanisms of antimycobacterial drug actions; (2) the development of resistance; (3) the slow growth & intracellular location of mycobacteria; (4) the chronic nature of mycobacterial disease, which requires protracted drug treatment and is associated with drug toxicities; and (5) patient compliance issues. Chemotherapy of mycobacterial infections almost always involves the use of drug combinations to delay the emergence of resistance and to enhance antimycobacterial efficacy.